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INTRODUCTION
Behçet’s disease (BD) is a chronic relapsing multi-systemic 
inflammatory disease of an unknown etiology characterized 
by repeated oral and genital ulcerations, ocular lesions, skin 
manifestations, arthritis, vasculitis, and gastrointestinal involve-
ment.1-3 Intestinal BD occurs in 3–60% of patients with BD.2-4 
East Asian countries such as Korea and Japan tend to have a 
higher frequency of gastrointestinal involvement of BD than 
Western or Middle Eastern countries.5 Although clinical mani-
festations of intestinal BD vary widely from mild abdominal 
pain to bowel perforation or massive hemorrhage, gastroin-
testinal involvement of BD often predicts poor treatment re-
sponse and unfavorable prognosis of the affected patients.5-7 
Intestinal BD and inflammatory bowel disease (IBD) share 
a considerable number of genetic backgrounds, pathogenesis, 
and clinical features. Moreover, current therapeutic strategies 
for intestinal BD have many similarities to those of IBD. Some 
experts classify the two diseases as the same category of a sin-
gle disease or as different spectrums of the same disease; oth-
ers regard them as totally different diseases. In this review, we 
will discuss the similarities and differences between intestinal 
BD and IBD (Table 1).
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Behçet’s disease (BD) is a multi-systemic inflammatory disorder of an unknown etiology and shows a chronic recurrent clinical 
course. When the disease involves the alimentary tract, it is called intestinal BD because of its clinical importance. Intestinal BD is 
more frequently reported in East Asian countries than in Western or Middle Eastern countries. While any part of the gastrointesti-
nal tract can be involved, the most common location of intestinal BD is the ileocecal area. A few, large, deep ulcerations with dis-
crete border are characteristic endoscopic findings of intestinal BD. Currently, there is no single gold standard test or pathogno-
monic finding of intestinal BD. However, recently developed novel diagnostic criteria and a disease activity index have helped in 
assessing intestinal BD. As intestinal BD shares a lot of characteristics with inflammatory bowel disease, including genetic back-
ground, clinical manifestations, and therapeutic strategies, distinguishing between the two diseases in clinical practice is quite 
difficult. However, biologic agents such as anti-tumor necrosis factor α antibody shows a considerable efficacy similar to inflam-
matory bowel disease cases. It is important to distinguish and treat those two disease entities separately from the standpoint of 
precise medicine. Clinicians should require comprehensive knowledge regarding the similarities and differences between intes-
tinal BD and inflammatory bowel disease for making an accurate clinical decision.
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ETIOLOGY AND PATHOPHYSIOLOGY
Genetics
The exact etiology and pathophysiology of BD remains unclear. 
Nevertheless, similar to IBD, both genetic and environmental 
factors might contribute to the development of BD.8 Classical-
ly, an human leukocyte antigen (HLA)-B51 allele has been 
thought to be the most important genetic factor of BD.9 Al-
though it is still unclear whether this locus independently acts 
as the fundamental cause of BD development, studies of BD 
report that the prevalence of the HLA-B51 allele is much high-
er in patients with BD than in unaffected populations.3,10 Ge-
nome-wide association studies (GWAS) from Japan and Tur-
key have also confirmed HLA-B51 as a susceptible locus for 
BD.11,12 Another susceptibility locus, MHC class I related gene 
A (MICA), has been evaluated in several studies.8,13,14 Howev-
er, an independent contribution for these loci has not proven 
to be easy to confirm due to the strong linkage disequilibrium 
with HLA-B51.15 HLA-B51 or MICA has not been shown to be 
associated with IBD susceptibility. 
Recent studies report an association for BD with interleukin 
(IL) 10 and the IL23R-IL12RB2 loci.11,12 Decreased mRNA ex-
pression and low protein production was correlated with BD 
expression. Similarly, IL10 or IL23R variants were also observed 
in IBD patients, suggesting that the two diseases have similar 
genetic backgrounds and pathogenesis.16 However, polymor-
phisms of genetic variants of IL10 and IL23R in patients with 
intestinal BD were not associated with those of IBD.17 The IL10-
1082AA and -819T genotype were associated with BD, while 
IL10-819CT and -592CA polymorphisms were related with ul-
cerative colitis. IL10-1082GA was not associated with IBD.18,19 
IBD is known to exhibit an association with variants in IL23R, 
IL12B, and TYK2, while BD is associated with the intergenic 
region between IL23R and IL12RB2.20 In the Korean popula-
tion, haplotypes of IL17A demonstrated a risk of developing 
intestinal BD, while those of IL23R were associated with dis-
ease protection.21
Close overlap of genetic variants provides considerable ex-
planation about phenotypic and clinical similarities between 
intestinal BD and IBD. Despite many parallels between the 
two diseases, detailed distinctions regarding genetics have 
been steadily traced. Therefore, further studies are needed to 
discover the exact genetic contributions for each disease. 
Microorganisms and immune response
Although BD shows familial aggregation and a genetic back-
ground, environmental factors also contribute to triggering in-
flammation. Increased Th1, Th17, CD4+ and CD8+ T cell, and 
γδ+ T cell activities were found both in the serum or inflamed 
tissues of BD patients,14,22-25 which suggests that innate and 
Table 1. Similarities and Distinctions of Intestinal Behçet’s Disease (BD) with Crohn’s Disease
Similarities Distinctions
Genetics Interleukin (IL)-10 and the IL-23R-IL-12RB2 loci
Human leukocyte antigen-B51 allele
MHC class I related gene A
Immunology
Activation of innate and adaptive immune system
Increased Th1, Th17, CD4+ and CD8+ T cell, and γδ+ T cell activities
Increased Th1-type cytokines 
The rate of anti-Saccharomyces cerevisiae antibodies   
  detection is remarkably higher
Bacterial contribution to the disease development
Serum anti-Herpes simplex virus-1 antibodies in the  
  patients with BD were significantly higher than controls
Heat shock protein (HSP) stimulate γδ+ T cells in BD patients  
  because of homology between Streptococcus sanguis  
  and human HSP
Anti-endothelial cell antibody
Clinical findings
Wide variation of abdominal symptoms from mild discomfort  
  to hematochezia
Similar extra-intestinal manifestations
Rare anorectal involvement in intestinal BD
Possible ischemic damage from vasculitis
Endoscopic findings
Segmental involvement
Various type of ulcerations are able to seen
Grossly normal looking intervening mucosa
Mucosal healing is closely related with favorable clinical course
Fewer number of lesion
Large size of ulceration
Round or oval shaped ulceration
Relatively more discrete and elevated border of ulceration
Histologic findings Non-specific inflammation (lymphocytic or neutrophilic infiltrations)
Vasculitis can be seen
Absence of non-caseating granuloma
Disease activity index
Concordance with clinical disease activity
Discordance with endoscopic disease activity
Highly weighted general condition of patient and  
  abdominal pain
Less concern for laboratory test and diarrhea
Treatment
5-amino-salicylates/sulfasalazine, corticosteroids, thiopurines,  
  thalidomide, and biologic agents are used for intestinal lesion
Concomitant use of medications for systemic BD is frequent
Prognosis Similar admission, operation, and post-operative recurrence rate
Higher cumulative rate in use of corticosteroids and  
  immunomodulators
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adaptive immunity act together to initiate BD. Similar to other 
autoimmune disorders, BD shows Th1-type cytokine profiles. 
IL-2 and interferon (INF)-γ producing T cells were increased 
in patients with active BD, while IL-4 producing T cells were 
lower than in controls.26 IL-12 and tumor necrosis factor (TNF)-α 
levels were also increased in BD.26-28 However, contrary to typ-
ical autoimmune disorders, CD5+CD19+ B cell levels were 
low, and autoimmune markers such as antinuclear antibodies 
were negative.14 The immunologic pathogenesis of IBD is 
summarized as exhibiting dysfunctions of the epithelial barri-
er, innate immune cells, and adaptive T cells.29 In patients 
with IBD, innate (macrophage, neutrophil) and acquired (T 
and B cell) immune responses are activated.30 Most pro-in-
flammatory cytokines involved in innate immune system are 
activated in both Crohn’s disease and ulcerative colitis. As in 
BD, Th1 and Th17 related cytokines, such as IL-12, IL-23, and 
IL-27, are also up-regulated in Crohn’s disease.31 Moreover, 
Th1 cell-related cytokines, such as IFN-γ and IL-2, are also in-
creased in Crohn’s disease.32 In patients with ulcerative colitis, 
however, T cells from the lamina propria highly produce IL-5 
and IL-13, which are regarded as Th2-cell related cytokines.32 
So far, relatively less research has been conducted on the im-
munology of BD.
Serum anti-herpes simplex virus (HSV)-1 antibodies in pa-
tients with BD were significantly higher than those in con-
trols,33 and HSV DNA was found in the genital and intestinal 
ulcers of patients.34 Sohn, et al.35,36 developed and reported a 
BD murine model through HSV inoculation in ICR mice. 
However, antiviral therapy seems controversial for the treat-
ment of BD. Though other viruses, including hepatitis C, par-
vovirus B19, cytomegalovirus, Epstein-Barr virus, and varicel-
la zoster virus, may contribute to BD, results are inconsistent.37 
The exact role of viruses in the pathogenesis of IBD is not 
clearly demonstrated.38-40 Cytomegalovirus is frequently relat-
ed with severe or steroid refractory ulcerative colitis.41 Cyto-
megalovirus seems to be associated with steroid refractori-
ness. However, the causal relationships between ulcerative 
colitis and cytomegalovirus are not clear.41,42
Generally, BD starts from oral ulcerations. Therefore, bacte-
ria from normal flora of the oral mucosa have been evaluated 
as causative organisms. A number of Streptococcus species 
have been implicated. Streptococcus sanguis and its antibodies 
are repeatedly detected in the oral mucosa and sera of patients 
with BD.43 Streptococcus sanguis-related antigen (KTH-1) stim-
ulates IL-6 and INF-γ production in patients with BD.44 Strepto-
coccus sanguis antigen has a homology with a cellular mem-
brane protein called heat shock protein (HSP). Mycobacterial 
HSP-65 and human HSP-60 share over 50% of sequence ho-
mology,33 and HSPs have been found to stimulate γδ+ T cells 
in BD patients.45,46 Therefore, researchers have postulated that 
specific bacterial antigens induce mucosal HSP against bacte-
rial stimulation and concurrently activate T cells against intes-
tinal mucosa in BD patients. However, the exact role of those 
antigens as an inducer of primary autoimmunity remains ob-
scure.
In the same manner, intestinal microbiota may play an im-
portant role in IBD development. Dysbiosis of conventional 
microbiota, pathogenic stimulation of functionally altered 
commensal bacteria, host genetic defects in containing micro-
biota, and defective host immune regulation are generally ac-
cepted explanations of the pathogenesis of IBD.47 In a study 
comparing mucosal flora between 40 controls and 305 pa-
tients with an inflamed bowel, including 54 Crohn’s disease 
and 119 ulcerative colitis, concentrations of mucosa-associat-
ed bacteria were higher in patients with intestinal inflamma-
tion than in controls.48 Recent studies have revealed that the 
dysbiosis of intestinal microbiota in patients with IBD is char-
acterized by reduction in diversity, prominent depletion of 
Bacteroidetes and Firmicutes including Clostridium XIVa/IV, 
and growth of Actinobacteria and Proteobacteria.49-51 Myco-
bacterium avium subspecies paratuberculosis, adherent-inva-
sive Escherichia coli, Clostridium difficile toxin A and entero-
toxigenic Bacteroides fragilis have been thought to be possible 
pathogens of IBD.52-57 However, the exact relationships be-
tween these bacteria and induction of IBD have not been con-
firmed due to differences among individuals and consider-
able alterations of intestinal microbiota.
Clinical findings
Abdominal pain, diarrhea, melena, and hematochezia can 
occur in patients with intestinal BD.58-60 Clinical signs such as 
abdominal tenderness or a palpable mass on the affected area, 
fever, and weight loss are also noted.58 Gastrointestinal mani-
festations of BD usually develop 4.5–6 years after the onset of 
oral ulcerations.5 Sometimes, however, intestinal lesions can 
precede extra-intestinal manifestations.61 Theoretically, there 
are two forms of intestinal lesions: one is mucosal inflamma-
tions and ulcerations by neutrophilic phlebitis. The other in-
volves ischemic damage from vasculitis.5 The most frequently 
involved location is the ileocecal area. However, any part of 
the alimentary tract and extra-intestinal organs, such as liver, 
pancreas, or spleen, can be affected. While anal complication 
is frequently observed in patients with Crohn’s disease, rectal 
or anorectal involvement of intestinal BD is rare.62 Also, intes-
tinal complications such as stricture, fistula, and abscess for-
mation are more frequent in patients with Crohn’s disease due 
to its transmural nature of inflammation.62 Oral ulceration is 
usually considered separately, because oral ulceration plays a 
major role in diagnosing BD.3 Although the frequencies of 
gastrointestinal involvement in patients with BD have been 
reported variously, depending on geographical location, its ac-
tual incidence might be higher than study results, because of 
the possible presence of asymptomatic lesions. A Chinese 
study evaluating screening colonoscopies of systemic BD pa-
tients found 35.1% had gastrointestinal lesions. Of them, four 
of 18 patients with active ulcerations showed no gastrointesti-
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nal symptoms.63 Importantly, extra-intestinal manifestations 
of BD, such as oral and genital ulcerations, ocular and join in-
volvement, and skin lesions, are all potentially experienced in 
the course of IBD. Thus, differential diagnosis between BD 
and IBD remains a challenge.
Endoscopic findings
Typical ulcerations of intestinal BD are described as a single 
or few, large, discrete, and round or oval shaped ulcerations in 
the ileocecal area.5,59 However, various ulcerations from small 
aphthous ulcerations to multiple irregular shaped ulcerations 
can be observed. As intestinal BD and Crohn’s disease share 
similar clinical courses, extra-intestinal manifestations, and 
non-specific gastrointestinal symptoms, it is often difficult to 
differentiate between the two.3 Lee, et al.64 compared colono-
scopic findings of 115 intestinal BD and 135 Crohn’s disease 
patients. Multivariate analysis revealed that round shape, few-
er number (≤5), focal distribution, and absence of aphthous 
and cobble stone appearance were independent discriminat-
ing factors of intestinal BD. Furthermore, they proposed a di-
agnostic algorithm using classification analysis (Fig. 1). Domi-
nant colonoscopic findings of intestinal BD also can be used. 
A study suggested a novel diagnostic criteria for intestinal BD 
using systemic and colonoscopic features of BD. Investigators 
regarded five or fewer lesions, oval shape, deep penetrating, 
discrete border, and ileocecal location as typical ulcerations. 
Overall, the positive predictive value and accuracy of the diag-
nostic algorithm were 86.1% and 91.1%, respectively.65 Kim, et 
al. classified macroscopic findings of intestinal BD ulcerations 
into volcano, geographic, and aphthous types. Volcano type 
ulceration (well-demarcated deeply penetrating ulcers with 
nodular margins, converging folds, or pseudopolyps) was as-
sociated with poor prognosis.66,67 Yim, et al.68 reported com-
plete resolution of inflammation by macro- and microscopic 
evaluation, so called “mucosal healing,” to be significantly as-
sociated with favorable clinical course, which is consistent 
with Crohn’s disease cases. Identifying active intestinal ulcer-
ations during clinical remission was independently related 
with clinical relapse. Classical endoscopic findings of Crohn’s 
disease in colonoscopic examination include discontinuous 
chronic mucosal inflammation, aphthoid ulcerations, longi-
tudinal ulcerations, and cobblestone appearance with normal 
surrounding mucosa.69 Skipped inflammatory lesions with 
normal intervening mucosa are frequently observed in Crohn’s 
disease, similar to those of intestinal BD. However, distribution 
patterns in patients with Crohn’s disease are more diffuse than 
in patients with intestinal BD (Fig. 2).64
Histologic findings
There are no pathognomonic histologic findings regarding in-
testinal BD. Vasculitis affecting small veins and venules are 
commonly accepted features.70 However, these findings are 
not consistently observed in affected organs. Histology from 
esophageal biopsy, for example, often shows non-specific in-
flammation (lymphocytic or neutrophilic infiltrations) rather 
than vasculitis.71 Generally, absence of non-caseating granu-
loma implies intestinal BD rather than Crohn’s disease. How-
ever, non-caseating granulomas are observed in only 15–36% 
of patients with Crohn’s disease.72 Other histologic characters 
of Crohn’s disease, such as transmural inflammation, chro-
nicity, and focality, are also able to be observed in intestinal 
BD. Normal circumferential mucosa surrounding a large ul-
ceration is one of the characteristic histologies of intestinal BD. 











Fig. 1. Diagnostic algorithm for differential diagnosis between intestinal Behçet’s disease and Crohn’s disease.
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patients with BD and 14 ulcerative colitis revealed that de-
struction of surface epithelium, polymorphonuclear infiltra-
tion, loss of goblet cells, and loss of crypts are more frequently 
observed in ulcerative colitis than in BD.73 
Disease activity index for intestinal Behçet’s disease 
(DAIBD)
The Korean IBD Study Group developed a novel tool for as-
sessing disease activity in patients with intestinal BD.74 As IBD 
exhibits an unpredictable wax-and-wane clinical course and 
various manifestations, disease activity should be monitored 
by an organized measuring method. Investigators have devel-
oped and applied several validated disease activity indices for 
each Crohn’s disease and ulcerative colitis.75-79 Before devel-
oping disease activity index for intestinal Behçet’s disease 
(DAIBD), some clinicians had used disease activity index of 
Crohn’s disease for evaluating intestinal BD activity. DAIBD 
includes the general condition of a patient, extra-intestinal 
manifestations, intestinal complications, symptoms and signs, 
and stool frequency. Whereas taking antidiarrheal agents and 
the presence of complications are highly weighted in Crohn’s 
disease activity index (CDAI), DAIBD considers the general 
condition of patient and abdominal pain more importantly. 
Based on the cumulative score of each item, disease activity is 
categorized into “severe,” “moderate,” “mild,” and “quiescent”. 
DAIBD showed much higher responsiveness than the CDAI 
(r=0.812 vs. r=0.645, respectively). However, a recent study of 
the same group revealed that DAIBD was not highly associat-
ed with endoscopic severity, which is similar to Crohn’s dis-
ease cases.80
Serologic tests
The rate of anti-Saccharomyces cerevisiae antibodies (ASCA) 
detection is remarkably higher in patients with BD, especially 
in patients with gastrointestinal involvement, than in con-
trols.81 In a study evaluating ASCA and the clinical course of in-
testinal BD patients, similar to those of Crohn’s disease, ASCA 
was positive in 44.3% of intestinal BD patients. ASCA positive 
patients were also more likely to receive surgical treatment.82 
The results further implied a similarity between Crohn’s dis-
ease and intestinal BD. However, atypical or perinuclear anti-
neutrophil cytoplasmic autoantibody was not shown to be re-
lated with intestinal BD.83 Studies regarding anti-endothelial 
cell antibody (AECA) revealed a high prevalence of AECA in 
systemic vasculitis including BD.84 α-enolase protein is the 
target of AECA.85,86 Serum soluble triggering receptor ex-
pressed in myeloid cells-1 was significantly associated with 
DAIBD in intestinal BD patients, although not with C-reactive 
protein (CRP) or erythrocyte sedimentation rate.87
TREATMENT AND PROGNOSIS
Medical treatments
There is a lack of randomized prospective studies regarding 
the treatment of intestinal BD.88,89 Traditionally, therapeutic 
implications of intestinal BD have been similar to those of 
Crohn’s disease.60,89 There is a controversy about the therapeu-
tic effects of 5-amino-salicylates (5-ASA)/sulfasalazine, which 
is routinely used in patients with IBD.90-92 In a retrospective 
cohort study investigating 143 patients with intestinal BD re-
ceiving 5-ASA/sulfasalazine alone for maintaining remission, 
cumulative relapse rates at 1, 3, 5, and 10 years after remission 
were 8.1%, 22.6%, 31.2%, and 46.7%, respectively. Younger age 
at diagnosis (<35 years), higher serum CRP level (1.5 mg/dL), 
and greater DAIBD score (≥60) independently predicted clini-
cal relapse.93 
Systemic corticosteroids are available for inducing remis-
sion in patients with moderate to severe disease or when treat-
ment with 5-ASA/sulfasalazine fails.94 Starting 0.5–1 mg/kg of 
prednisolone or its equivalent and rapid tapering strategies are 
prevalent, similar to IBD treatment.95 The dose of corticoste-
Fig. 2. Endoscopic findings of intestinal Behçet’s disease (A) and Crohn’s disease (B).
A B
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roids should be adapted according to the severity of the dis-
ease.3 In a retrospective cohort study, systemic corticosteroid 
therapy (mean starting dose, 0.58 mg/kg) in 54 patients with 
active intestinal BD showed 46.3% complete remission, 42.6% 
partial remission, and 11.1% no response after a month from 
treatment. After one year, however, prolonged responses were 
found in 4 only 8.1% of the cohort, while 35.2% of patients 
showed corticosteroid dependency.96 Compared with a simi-
lar study evaluating clinical outcomes in patients with Crohn’s 
disease receiving oral prednisolone, prolonged response 
(56.6%) and corticosteroid dependency (24.1%) at a year after 
receiving treatment showed a better clinical course in patients 
with Crohn’s disease than in intestinal BD.97 
Thiopurines or azathioprine/6-mercaptopurine (AZA/6-
MP) are indicated in patients who show corticosteroid depen-
dency or resistance.95 In a double-blind, randomized, place-
bo-controlled trial, AZA had a beneficial effect in controlling 
BD including eye and extra-ocular diseases.98 In patients with 
intestinal BD, Jung, et al.99 reported cumulative relapse rates 
of 5.8%, 28.7%, 43.7%, and 51.7% at 1, 2, 3, and 5 years after re-
mission among patients who received AZA/6-MP for remis-
sion maintenance, respectively. Multivariate analysis showed 
a young age at diagnosis (<25 years) and lower serum hemo-
globin level (<11 g/dL) to be independent predictors of re-
lapse. Similarly, a retrospective study revealed cumulative re-
lapse rates of 18.0% and 49.2% in patients with Crohn’s disease 
who were treated continuously with AZA/6-MP to maintain 
clinical remission after 1 and 3 years of treatment, respective-
ly. Independent predictive factors of relapse during AZA/6-
MP treatment were younger age at treatment and increased 
serum CRP level at remission status.100
Thalidomide (100–300 mg/day) was found to be effective 
on treating oral and genital ulcerations, as well as follicular le-
sions, of BD in a randomized, double-blind, placebo-con-
trolled study.101 Another small case series reported that thalid-
omide (1–3 mg/kg) was able to replace steroid therapy without 
serious complications in juvenile-onset intestinal BD.102 A 
small study investigating thalidomide in patients with IBD re-
ported clinical response rates of 83.3% and 100.0% after 12 
weeks of 100–400 mg per day thalidomide treatment in pa-
tients with Crohn’s disease and ulcerative colitis, respective-
ly.103 However, continuous vigilance for long-term side effects 
of thalidomide is warranted. 
Monoclonal antibodies to TNF-α, including infliximab (IFX) 
and adalimumab (ADA), are important biological agents for 
treating IBD.30 After several reports104-108 on therapeutic effects 
of anti-TNF-α in patients with intestinal BD, accumulation of 
evidence on the therapeutic impacts of anti-TNF-α treatment 
has increased. Nevertheless, there is a need to investigate the 
impact of anti-TNF-α treatment on cumulative surgery rates 
and post-operative recurrence. Currently, there is no large 
scale, randomized trial of anti-TNF-α agents in patients with 
intestinal BD. However, several case series reported favorable 
results of IFX on induction and maintain remission of intesti-
nal BD.109-111 A retrospective multicenter study in Korea, evalu-
ating 28 cases of patients with intestinal BD treating with IFX 
who were refractory to conventional medical treatments, re-
ported a clinical response rate of 64.8% at 4 weeks after treat-
ment.112 Older age (≥40 years), female gender, longer disease 
duration (≥5 years), using concomitant immunomodulators, 
and achieving clinical remission were independently associ-
ated with sustained response. A prospective, multicenter, ran-
domized, double-blind, placebo-controlled study (ACCENT I) 
revealed that IFX induced clinical remission (CDAI<150) in 
58% of patients with Crohn’s disease.113 Also, patients who re-
ceived scheduled IFX were more likely to sustain clinical re-
mission than those who did not.114 The impacts of mainte-
nance therapy with IFX were consistently confirmed, even in 
patients with fistulizing Crohn’s disease who responded to in-
duction therapy (ACCENT II).115
Recently, the clinical efficacy of ADA was also ascertained 
by case reports116-118 and a small randomized trial119 similar to 
IFX. A phase III, multicenter, open-label, uncontrolled study 
investigating the efficacy and safety of ADA for treating 20 ac-
tive intestinal BD patients who were refractory to convention-
al therapy in Japan revealed complete remission in 20% at 
week 52 with similar rates of adverse events as in other clinical 
trials regarding ADA.119 Two randomized, double-blind, pla-
cebo-controlled studies similarly evaluated the efficacy of re-
mission induction and maintenance of ADA in patients with 
Crohn’s disease. A study investigating 299 patients with mod-
erate-to-severe Crohn’s disease naive to anti-TNF-α agents 
who were randomized to receive ADA (40/20 mg, 80/40 mg, 
or 160/80 mg) or placebo at weeks 0 and 2 showed remission 
rates of 18%, 24%, and 36% of (CDAI<150) at week 4, respec-
tively.120 A follow-up study revealed that 40 mg of ADA injec-
tion every other week or weekly showed significantly higher 
remission rates (79% and 83%, respectively) at week 56 than 
placebo (44%, p<0.05).121 Another study evaluating 854 pa-
tients with moderate to severe Crohn’s disease who received 
80 mg of ADA at week 0 and 40 mg at week 2 showed clinical 
response in 58.4% (drop in CDAI of 70 points) at week 4. Also, 
40% of the 40 mg every other week group, 47% of the 40 mg 
weekly group, and 17% of the placebo group were in remis-
sion at week 26.122 A consensus statement of anti-TNF-α thera-
py in patients with intestinal BD by the Japanese group pro-
posed its indication as a standard therapy for intestinal BD.123 
However, a large scale, randomized, prospective trial is need-
ed for the establishment of the long-term efficacy of anti-
TNF-α therapy.
Surgical treatment
Surgical resection of an affected bowel is considered when 
patients with intestinal BD are refractory to medical treatment 
or serious complications, such as bowel perforation or severe 
bleeding, cannot be controlled by conservative treatment.124 
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Lee, et al.125 reported peritonitis due to multiple perforations 
was the most common indication of surgery in patients with 
intestinal BD, following gastrointestinal bleeding, entero-cu-
taneous fistula, and intractable pain with recurrence. Bowel 
perforation is one of the most disastrous complications of in-
testinal BD. A retrospective analysis regarding free bowel wall 
perforation in 129 patients with intestinal BD reported that 33 
(25.6%) of patients experienced bowel perforation and con-
secutive surgery. Of them, 14 (42.4%) showed post-operative 
recurrence and 11 (33.3%) underwent re-operation. Younger 
age at diagnosis (≤25 years), experience of prior laparotomy, 
and volcano-shaped ulceration predicted bowel perforation 
independently.126 
Compared to Crohn’s disease, intestinal BD shows similar 
cumulative surgery rates (29.4% and 36.0% in Crohn’s disease 
vs. 31.6% and 44.4% in intestinal BD at five and ten years, re-
spectively: p=0.287).124 Naganuma, et al.127 reported that small 
bowel involvement and ocular lesion in patients with intesti-
nal BD were significantly associated with requiring surgery. 
Likewise, pouchitis after ileal pouch-anal anastomosis in pa-
tients with IBD was highly related with extra-intestinal mani-
festations.128 However, intestinal BD surgery shows distinct 
features. While the extent of bowel resection should be restrict-
ed in patients with Crohn’s disease,129 that of intestinal BD is 
still controversial. Traditionally, resecting a sufficient margin 
including normal intestine was recommended in surgery of 
intestinal BD.6,130,131 However, more recent investigators have 
asserted minimal resection, which is restricted in affected 
bowel, because resection length was not related with post-op-
erative recurrence in patients with intestinal BD.58,124,132 Due to 
relatively high rates of complications at anastomosis sites, in-
cluding leakage, perforation, and fistula formation, in intesti-
nal BD surgery, bowel diversion (stoma formation) is suggest-
ed by several investigators.133 Especially, because pathergy is 
often seen with BD patients, ulcerations at the site of surgical 
incision can develop.134 
Prognosis
A study investigating the clinical course of intestinal BD dur-
ing the first 5 years after diagnosis reported that 74.6% of pa-
tients were in remission or showed mild disease activity at 
years 5. The independent predictor of severe clinical course 
was higher DAIBD (≥40) at diagnosis (OR: 6.2, 95% CI: 1.1–
33.5, p=0.035).135 The same group also compared long-term 
clinical outcomes between intestinal BD and Crohn’s disease. 
The cumulative probabilities of surgery, hospital admission, 
and post-operative recurrence were not significantly different 
between intestinal BD and Crohn’s disease (44.4% vs. 36.0%, 
69.2% vs. 73.8%, and 66.5% vs. 79.1% at 10 years, p=0.287, 0.295, 
and 0.724, respectively).136 However, there were significant dif-
ferences in cumulative probabilities of corticosteroid use and 
immunosuppressant use between intestinal BD and Crohn’s 
disease (59.4% vs. 42.6% and 37.7% vs. 27.1%, p<0.001 and 
<0.001, respectively).136
CONCLUSIONS
The clinical manifestations of intestinal BD and IBD frequent-
ly overlap. Therefore, clinicians often encounter formidable 
obstacles regarding differential diagnosis at first presentation. 
Intestinal BD and Crohn’s disease share similar genetic back-
grounds, such as IL10 and the IL23R-IL12RB2 locus. Innate 
and adaptive immune responses activate Th1, Th17, CD4+ 
and CD8+ T cell, and γδ+ T cells from the stimulation of mi-
croorganisms alike. However, precise generic variants and the 
mechanisms of immune responses are different between the 
two diseases. Although clinical manifestations and endoscop-
ic findings resemble each other, independent characteristics 
can be found through careful clinical evaluation. So far, treat-
ment strategies for IBD have proven to be the most effective 
for controlling intestinal BD. However, in terms of under-
standing disease, continued efforts to out the pathogenesis 
and to distinguish intestinal BD from other inflammatory 
conditions, including Crohn’s disease, must be pursued.
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